Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 July 2020 | Story Nonsindiso Qwabe | Photo Supplied
Tau Tladi.

In times of great difficulty, a tale of hope goes a long way in encouraging one to persevere. Tau Tladi, a second-year LLB extended-programme student who was diagnosed with ataxia – a degenerative disease of the nervous system – at a young age, has conquered many adversities. He is living his life to the fullest, pursuing his dream of becoming a lawyer one day. Because of a brain injury during birth, Tladi struggles to speak, write, or walk. On campus, he makes use of a scribe and reader to write his tests and exams. 

Learning from others key to success

“Living with ataxia means I have improper speech, I struggle to walk properly, my hands can’t grab things properly, and I can’t even write with them.   Seeing other people living with disabilities and still pursuing their dreams has inspired me a lot; it made me realise that I too have the ability to achieve my dreams,” he said. 
While this disability presented him with many hindrances in life, it has never held him back. “Growing up was challenging because I was not able to develop like other children. As I got older, I could not experience some of the things that other kids could do, such as playing and running around,” he said.

Triumph in the face of adversity
 
Despite all the challenges, Tau completed his matric in 2016 and was even named as one of the top 100 achievers in the Free State. He describes his admission to the LLB programme as a dream come true. “I have always wanted to study an LLB degree. It is the best feeling ever to be at university and studying something that I always wanted to do. I would love to become an attorney.”

Tladi hopes to finish his degree in 2021. He is also an avid sportsman, having participated in the Free State paracycling team and winning first place at the national competition. 

“Living with disability has never been easy for me, so I have learned to be grateful and use every opportunity that I come across and work very hard to fulfil my dreams.”

Hanlie Grobler, Senior Officer in the Faculty of Law, described Tladi as a remarkable young man who always wears a smile on his face. “If you are feeling a bit blue today, cheated by COVID-19, that life is unfair to you – remember this young man who is an excellent example of determination, and do what you have to do, to the best of your ability, and be thankful for what you have.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept